Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study
Cancer Medicine · 2024
DOI: 10.1002/cam4.7349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shuo Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Endostatins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Science and Technology Innovation Medical Development Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 2 probably cannot tolerate chemotherapy or other antitumor therapies. Some studies have reported that immunotherapy combined with antiangiogenic therapy is well‐tolerated and shows good antitumor activity. However, the efficacy of this combination as a later‐line therapy in patients with ECOG PS 2 is unclear. This study evaluated the effectiveness and safety of this combination strategy as third‐ or further‐line therapy in stage IV non‐small cell lung cancer (NSCLC) patients with ECOG PS 2.
Methods
In this retrospective study, patients treated with camrelizumab plus antiangiogenic therapy (bevacizumab, anlotinib, or recombinant human endostatin) were included. Objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), quality of life (QOL) assessed by ECOG PS, and safety were analyzed.
Results
Between January 10, 2019, and February 28, 2024, a total of 59 patients were included. The ORR was 35.6% (21/59) and the DCR was 86.4%. With a median follow‐up of 10.5 months (range: 0.7–23.7), the median PFS was 5.5 months (95% confidence interval [CI]: 3.8–7.3) and the median OS was 10.5 months (95% CI: 11.2–13.6). QOL was improved (≥1 reduction in ECOG PS) in 39 patients (66.1%). The most common Grade 3–4 treatment‐related adverse events were hepatic dysfunction (6 [10%]), hypertension (5 [8%]), and hypothyroidism (3 [5%]). There were no treatment‐related deaths.
Conclusions
Third‐ or further‐line immunotherapy combined with antiangiogenic therapy is well‐tolerated and shows good antitumor activity in stage IV NSCLC patients with ECOG PS 2. Future large‐scale prospective studies are required to confirm the clinical benefits of this combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China.
- Department of Orthopedics, Binzhou Medical University Hospital, Binzhou, Shandong, People's Republic of China.
ORCID-Profile: Shuo Li, Li-Jun Tian
Förderung
- Beijing Science and Technology Innovation Medical Development Foundation
Zitieren
APA
Li, S., Yu, Z. S., Liu, H. Z., Li, S. J., Wang, M. Y., Ning, F. L., & Tian, L. J. (2024). Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.7349
Vancouver
Li S, Yu ZS, Liu HZ, Li SJ, Wang MY, Ning FL, et al. Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study. Cancer Medicine. 2024. doi:10.1002/cam4.7349
BibTeX
@article{Li2024,
author = {Li, Shuo and Yu, Ze-Shun and Liu, Hong-Zhi and Li, Shu-Jing and Wang, Ming-Yue and Ning, Fang-Ling and Tian, Li-Jun},
title = {Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7349}
}
EUVIMED